RET and neoplasm: Investigations into the efficacy and safety of selpercatinib in a RET fusion-positive tumour-agnostic population of 45 patients with non-lung, non-thyroid advanced solid tumours in LIBRETTO-001 showed clinically meaningful efficacy, an ORR of 43.9% (95% CI, 28.5–60.3%) in 41 efficacy-evaluable patients, and a safety profile similar to that seen in other indications (86).